- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
NervGen Pharma Corp (NGEN)
NervGen Pharma Corp stock price live, this page displays TSXV NGEN stock exchange data. View the NGEN premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the NervGen Pharma Corp real time stock price chart below.
What Is the NervGen Pharma Corp Stock Price Today?
The NervGen Pharma Corp stock price today is 3.61.
What Is the Stock Symbol for NervGen Pharma Corp?
The stock symbol for NervGen Pharma Corp is ""NGEN.""
What Stock Exchange Does NervGen Pharma Corp Trade On?
NervGen Pharma Corp is listed and trades on the TSXV stock exchange.
Is NervGen Pharma Corp a Good Stock to Buy?
Determining whether NervGen Pharma Corp—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the NGEN quote. (ISIN: CA64082X2032)
What Is the NervGen Pharma Corp Stock Price Today?
The NervGen Pharma Corp stock price today is 3.61.
What Is the Stock Symbol for NervGen Pharma Corp?
The stock symbol for NervGen Pharma Corp is ""NGEN.""
What Stock Exchange Does NervGen Pharma Corp Trade On?
NervGen Pharma Corp is listed and trades on the TSXV stock exchange.
Is NervGen Pharma Corp a Good Stock to Buy?
Determining whether NervGen Pharma Corp—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the NGEN quote. (ISIN: CA64082X2032)
TSXV
Currency in CAD
3.61
-0.10(-2.70%)
Closed·
Fair Value
An estimate of a NervGen Pharma's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
3.60
3.76
52 wk Range
2.05
7.05
NGEN Scorecard
Full Analysis
Suffers from weak gross profit margins
NGEN is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a NervGen Pharma's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
3.603.76
52 wk Range
2.057.05
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
NGEN Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a NervGen Pharma's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Price Target
7.10
Upside
+96.68%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Analysts do not anticipate the company will be profitable this year
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy
NervGen Pharma Corp Company Profile
NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company’s lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer’s disease; and NVG-300, which is in a preclinical model of ischemic stroke and confirmatory SCI study. NervGen Pharma Corp. has a licensing agreement with Case Western Reserve University to develop and commercialize a patented technology with therapeutic potential for spinal cord injury and other conditions associated with nerve damage. The company was incorporated in 2017 and is based in Vancouver, Canada.
Compare NGEN to Peers and Sector
Metrics to compare | NGEN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipNGENPeersSector | |
|---|---|---|---|---|
P/E Ratio | −9.8x | −0.8x | −0.5x | |
PEG Ratio | 3.28 | 0.00 | 0.00 | |
Price/Book | −288.0x | 1.1x | 2.6x | |
Price / LTM Sales | - | 0.8x | 3.3x | |
Upside (Analyst Target) | 89.8% | 6.1% | 38.9% | |
Fair Value Upside | Unlock | 15.0% | 5.4% | Unlock |
Analyst Ratings
4 Buy
0 Hold
0 Sell
Ratings:
4 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 7.10
(+96.68% Upside)
Earnings
Latest Release
Aug 27, 2025
EPS / Forecast
-0.13 / -0.075
Revenue / Forecast
-- / --
People Also Watch
FAQ
What Stock Exchange Does NervGen Pharma Trade On?
NervGen Pharma is listed and trades on the TSX Venture Exchange stock exchange.
What Is the Stock Symbol for NervGen Pharma?
The stock symbol for NervGen Pharma is "NGEN."
What Is the NervGen Pharma Market Cap?
As of today, NervGen Pharma market cap is 264.53M.
What Is NervGen Pharma's Earnings Per Share (TTM)?
The NervGen Pharma EPS (TTM) is -0.38.
When Is the Next NervGen Pharma Earnings Date?
NervGen Pharma will release its next earnings report on 12 Nov 2025.
From a Technical Analysis Perspective, Is NGEN a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has NervGen Pharma Stock Split?
NervGen Pharma has split 0 times.
How Many Employees Does NervGen Pharma Have?
NervGen Pharma has 0 employees.
What is the current trading status of NervGen Pharma (NGEN)?
As of 30 Aug 2025, NervGen Pharma (NGEN) is trading at a price of 3.61, with a previous close of 3.71. The stock has fluctuated within a day range of 3.60 to 3.76, while its 52-week range spans from 2.05 to 7.05.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.